Lower Risk of New‐Onset Atrial Fibrillation in Conduction System Pacing Compared With Right Ventricular Pacing

作者：Feng Li, You Zhang, Jian Huang, Si‐Liang Peng, Meng‐Chao Jin, Chi Geng, Venkatesh Ravi, Parikshit S. Sharma, Pugazhendhi Vijayaraman, Hui Li · 发表于：Pacing and Clinical Electrophysiology · 年份：2025 · DOI：10.1111/pace.15121 · 被引用次数：7 · 研究领域：Cardiac pacing and defibrillation studies、Cardiac Arrhythmias and Treatments、Mechanical Circulatory Support Devices

BACKGROUND: Conduction system pacing (CSP) has been reported to improve clinical outcomes in comparison of right ventricular pacing (RVP). However, the performance between CSP and RVP on the risk of new-onset atrial fibrillation (AF) remains elusive. METHODS: Four online databases were systematically searched up to July 1, 2024. Studies comprising the rate/risk of new-onset AF between CSP and RVP group were included. Subgroup analysis was performed to screen the potential determinants for the new-onset AF risk for CSP therapy. The pooled risk of new-onset AF based on ventricular pacing burden (Vp) between CSP and RVP group were evaluated. RESULTS: A total of six studies including 1577 patients requiring pacing therapy were eligible. The pooled new-onset AF rates for CSP and RVP group were 0.09 and 0.27, respectively. Compared with RVP group, CSP group showed a lower pooled risk (risk ratio [RR] 0.38, p = 0.000) and adjusted risk (hazard ratio [HR] 0.32, p = 0.000) of new-onset AF. Meanwhile, a significant intervention-covariate interaction for the adjusted risk of new-onset AF between CSP and RVP group was identified with Vp < 20% and Vp ≥ 20%. CONCLUSIONS: Our study suggests that CSP is associate with a significantly lower occurrence of new-onset AF compared with RVP. The Vp ≥ 20% may be the key determinant on the lower risk of new-onset AF with CSP therapy. TRIAL REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023492551, identifier (CRD420234925...